2014 Annual Meeting | 2NF.001 - Neuro Flash: MRI and Multiple Sclerosis

Date Sunday 04/27/14

Time 06:30 AM - 08:00 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Neuro Flash

Director(s) Robert T. Naismith, MD, FAAN

Topic(s) General Neurology

Learning Objectives Participants should be able to determine when imaging of the brain and spinal cord is indicated in the evaluation of a patient with multiple sclerosis; utilize the initial MRI to help with treatment decision-making; devise a monitoring strategy to assure good clinical and subclinical response to a disease-modifying therapy; and understand how the MRI should impact a decision to recommend a switch in therapy, or an escalation in your monitoring strategy.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
06:30 AM - 06:35 AM		Introduction Robert T. Naismith, MD, FAAN
06:35 AM - 07:05 AM		MRI for Diagnosis, Prognosis, and Treatment Decisions in MS Eric Klawiter, MD, FAAN
07:05 AM - 07:35 AM		MRI for Assessing Optimal Response to MS Disease-modifying Therapy Robert T. Naismith, MD, FAAN
07:35 AM - 08:00 AM		Case-based Discussion: Implementing MRI Data into Treatment Decisions

Faculty Disclosures
Robert T. Naismith, MD, FAAN	Dr. Naismith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Naismith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Myers Squib. Dr. Naismith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Naismith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme. Dr. Naismith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Naismith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Naismith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celltrion. Dr. Naismith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Naismith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Naismith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Naismith has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Journal Watch.
Eric Klawiter, MD, FAAN	Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Galen/Atlantica. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Banner Life Sciences. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Greenwich Biosciences. Dr. Klawiter has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for OM1. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Klawiter has received research support from Biogen. The institution of Dr. Klawiter has received research support from Abbvie. The institution of Dr. Klawiter has received research support from Genentech.